Lung cancer is the most common cancer worldwide with 2.4 million cases per year & responsible for 1.8 million deaths worldwide in 2022.1 Roche diagnostic offers a unique breadth of menu and expertise combining four key technologies: tissue diagnostics, immunoassays, molecular diagnostics, and digital diagnostics. Our comprehensive tissue diagnostic solutions accelerate the pursuit of certainty in life-changing diagnostic decisions.
Roche offers the most comprehensive tissue diagnostics lung cancer portfolio with more than 40 antibodies — including the largest menu of companion diagnostics available — enabling confident diagnosis and stratification of lung cancer.
We are continually optimising our lung cancer core menu and expanding our companion diagnostics menu and indications. ALK IHC is superior to ALK FISH on small biopsies to predict tumor response and survival for patients with advanced NSCLC.2
Reduce cost and make more immediate treatment decisions with VENTANA® ALK (D5F3) CDx Assay. The assay was the IHC assay of choice for ALECENSA®, LORBRENA®, and ZYKADIA® clinical trials, eliminating the requirement for confirmatory FISH. VENTANA ROS1 (SP384) provides a cost-effective and efficient means of identifying cases with elevated ROS1 protein expression before confirming by another method, such as by FISH or NGS.3
You can be more effective with Roche PD-L1 CDx assays. The IVD tests are substantially more effective to aid clinicians in aligning PD-L1-positive NSCLC patients with immunotherapy — with the potential to lead to improved outcomes and a reduction in overall healthcare costs associated with disease progression, management of adverse events and end of life care.4
References
